Where is LifeEDIT located?

LifeEDIT is headquartered in Durham, United States.

Who is the current CEO of LifeEDIT?

Mitchell H Finer of LifeEDIT. They have also founded 1 company.

How many employees does LifeEDIT have?

As of May 31, 2026, the latest employee count at LifeEDIT is 25.

Where does LifeEDIT rank among its competitors?

LifeEDIT ranks 882nd amongst 2023 active competitors, of which 448 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was One Biosciences, which secured $3.76M in Sep, 2026.

Who are the top competitors of LifeEDIT?

LifeEDIT's top competitors include Antheia, Transcenta and Akeso. Among them, One Biosciences secured the most recent funding round in September, 2026.

LifeEDIT - 2026 Company Profile, Team & Competitors

Company Details

LifeEdit is a developer of gene therapy based therapeutics. The company has developed a genome editing platform with the collection of RNA-guided nucleases that are active in mammalian cells. The company is developing novel therapeutics in neuroscience, immuno-oncology, and stem cells. It also develops technologies for agriculture that address agronomic traits, quality traits, and accelerated breeding.

Key Metrics

Founded Year

2017

Location

Durham, United States

Stage

Acquired

Ranked

882^nd among 2023 active competitors

Employee Count

25 as on May 31, 2026

Similar Companies

Antheia & 2730 more

Exit Details

Acquired by ElevateBio (Oct 27, 2021)

View LifeEDIT's full profile

LifeEDIT got acquired by ElevateBio on Oct 27, 2021.

Click here to take a look at LifeEDIT's acquisition in detail

LifeEDIT has not raised any funding rounds yet.

LifeEDIT's employee count trend

LifeEDIT has 25 employees as of May 26. Here is LifeEDIT's employee count trend over the years:

Uncover LifeEDIT's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of LifeEDIT include Antheia, Transcenta and Akeso. Here is the list of Top 10 competitors of LifeEDIT, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Antheia 2013, Palo Alto (United States), Series C	Genetically engineered yeast cells to produce medicinal products	$176M	Viking Global Investors, ATHOS KG & 15 others	67/100
2nd	Transcenta 2019, Suzhou (China), Public	Developer of antibody-based therapeutics	$205M	Lilly Asia Ventures, Temasek & 11 others	66/100
3rd	Akeso 2012, Zhongshan (China), Public	Developer of antibody drug conjugates for the treatment of broad spectrum diseases	$195M	Loayal Valley Capital, Sino Biopharmaceutical ... & 18 others	65/100
4th	Korro Bio 2018, Cambridge (United States), Public	Provider of RNA editing technologies to develop genetic medicines for rare and prevalent diseases	$4M	Cormorant Asset Management, Atlas Venture ... & 14 others	64/100
5th	Novogene Corporation 2011, Beijing (China), Series B	Provider of genomic services and solutions	$75M	SDIC Innovation, CMB International Capital ... & 4 others	64/100
6th	Fermentalg 2005, Libourne (France), Public	Innovating with algae for sustainable solutions in nutrition and environmental impact	$30.3M	Demeter, Smalt Capital & 14 others	63/100
7th	Microban 1994, Huntersville (United States), Acquired	Antimicrobial and odor control technologies for durable product protection and freshness	$64.6M	TA Associates, UBS & 1 others	63/100
8th	LifeMine Therapeutics 2016, Watertown (United States), Series E	Developer of novel drugs from fungi via genome mining and recombinant overexpression	$563M	Fidelity Investments, 6 Dimensions Capital ... & 17 others	63/100
9th	One Biosciences 2020, Paris (France), Series A	Developer of single-cell therapeutics solutions to treat multiple health disorders	$22.4M	BLAST Premier, Redmile Group & 7 others	63/100
10th	Dewpoint Therapeutics 2018, Boston (United States), Series D	Developer of small molecule based therapeutics	$364M	Maverick Ventures, SoftBank Vision Fund & 16 others	62/100
882nd	LifeEDIT 2017, Durham (United States), Acquired	Developer of gene therapy based therapeutics	-	-	28/100